Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 4,175 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control comparison Clear all

Conditions: Hypertension
Interventions: Cellular Home blood pressure (BP) monitoring; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 85 Years
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Anesthesia
Interventions: Control - Transversus Abdominus Plane Block, Quadratus Lumborum Block; Procedure
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Diabetes Mellitus, Type 2
Interventions: Vildagliptin, metformin; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 78 Years
Enrollment: 914 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin glargine, Lispro Low Mix, Lispro Mid Mix, Lispro; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 30 Years to 79 Years
Enrollment: 2,091 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 138
States / cities: Mobile, Alabama • Litchfield Park, Arizona • Little Rock, Arkansas + 135 more

Conditions: Unilateral Transfemoral Amputation
Interventions: Not listed
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 70 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy Children, CP (Cerebral Palsy), CP, Cerebral Palsy
Interventions: Brain-Computer Interface (BCI)-HABIT-VR, Hand and Bimanual Intensive Therapy Virtual Reality (HABIT-VR); Device
Lead sponsor: University of Nebraska; Other
Eligibility: 6 Years to 17 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Staphylococcal Infection, Abscess, Staphylococcal Skin Infection, Folliculitis
Interventions: clindamycin, cephalexin; Drug
Lead sponsor: Aaron Chen; Other
Eligibility: 6 Months to 18 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Long COVID, Postural Orthostatic Tachycardia Syndrome, Dysautonomia, Myalgic Encephalomyelitis, Chronic Fatigue Syndrome, Long Covid19
Interventions: Wearable device; Device
Lead sponsor: Scripps Translational Science Institute; Other
Eligibility: 18 Years and older
Enrollment: 100,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Suicide, Accidental Injuries, Firearm Injury
Interventions: MI FSN - Lethal Means Reduction, Scripted FSN - Lethal Means Reduction, General Firearm Safety Intervention - General Firearm Safety, General Firearm Comparison - General Firearm Safety; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Kotzebue, Alaska

Conditions: Asthma, GERD
Interventions: Esomeprazole, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 961 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 27
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 24 more

Conditions: Muscle Relaxants
Interventions: Not listed
Lead sponsor: Shashi Bhatt, MD; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Toledo, Ohio

Conditions: HIV
Interventions: Predictive Analytics and Clinical Decision Support; Other
Lead sponsor: Harvard Pilgrim Health Care; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 16
States / cities: Fremont, California • Oakland, California • Oceanside, California + 13 more

Conditions: Depression Symptoms
Interventions: Creativity Camp; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 12 Years to 17 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Allergic Conjunctivitis
Interventions: RX-10045, Vehicle for RX-10045 arm; Drug
Lead sponsor: C.T. Development America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Corneal Epithelial Disorders
Interventions: SJP-0035 Ophthalmic Solution, Vehicle of SJP-0035 Ophthalmic Solution; Drug
Lead sponsor: Senju Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 17
States / cities: Little Rock, Arkansas • Glendale, California • Glendora, California + 14 more

Conditions: Type 2 Diabetes
Interventions: Retatrutide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 28
States / cities: Huntsville, Alabama • Sun City West, Arizona • Apple Valley, California + 24 more

Conditions: Indolent Systemic Mastocytosis
Interventions: Masitinib, Placebo, Best Supportive Care; Drug · Other
Lead sponsor: AB Science; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 2
States / cities: Sacramento, California • Houston, Texas

Conditions: Hpv, HPV 16 Infection, HPV Infection, High Risk HPV
Interventions: Teal Wand Self-Collection Device Group; Device
Lead sponsor: Teal Health, Inc.; Industry
Eligibility: 25 Years to 65 Years · Female only
Enrollment: 870 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 15
States / cities: Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 10 more

Conditions: Type 2 Diabetes Mellitus, Hyperglycemia, Hypoglycemia
Interventions: Freestyle Libre 3 Continuous Glucose Monitor (CGM); Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Dry Eye
Interventions: Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID, Vehicle Ophthalmic Solution (0.25% Novel Formulation) QID to BID; Drug
Lead sponsor: Aldeyra Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Breast Cancer
Interventions: Active Breathing Coordinator (ABC), Radiation Therapy; Device · Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Interstitial Lung Disease
Interventions: EBUS without stylet; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Autosomal Dominant Polycystic Kidney Disease
Interventions: Tolvaptan MR, Tolvaptan IR, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 35
States / cities: Huntsville, Alabama • Mobile, Alabama • Peoria, Arizona + 31 more

Conditions: Heart Failure With Preserved Ejection Fraction
Interventions: LCZ696, Valsartan; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 4,822 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 110
States / cities: Huntsville, Alabama • Mobile, Alabama • Muscle Shoals, Alabama + 92 more

Search by objective public record fields.

Remote Monitoring for Equity in Advancing Control of Hypertension

Quadratus Lumborum Versus Transversus Abdominis Plane Nerve Block: A Comparison Study

Efficacy/Safety of Vildagliptin and Metformin Combination Therapy in Patients With Type 2 Diabetes Not Well Controlled With Metformin Alone

The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)

A Comparison Between Ischial-Containment and Sub-Ischial Prosthetic Sockets to Determine Their Effects on Secondary Health Conditions

Training Upper Limbs of Neurodiverse Children by Connecting Brain Activities to a Virtual Reality Based Game

Comparison of Cephalexin Versus Clindamycin for Suspected CA-MRSA Skin Infections

The Long COVID-19 Wearable Device Study

Family Safety Net - Aim 3: Randomized Control Trial

Safety and Efficacy Study to Determine Anti-Asthmatic Effect of Esomeprazole Magnesium; Nexium Reflux Asthma

The Dose-Response Relationship of Rocuronium in Patients Taking Pyridostigmine

Predictive Analytics and Clinical Decision Support to Improve PrEP Prescribing

Measuring and Enhancing Creativity and Brain Flexibility in Adolescents With Depression

Evaluation of the Onset and Duration of Action of RX-10045 in Allergic Conjunctivitis

Safety and Efficacy Study of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders

Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis

SELF-CERV Pivotal Study: SELF-Collection for CERVical Cancer Screening

A Study of Glycemic Control in Left Ventricular Assist

A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye Disease

Using the Active Breathing Control Device to Reduce Radiation Side Effects to Critical Structures in Breast Cancer

Stylet vs No Stylet During EBUS TBNA

8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction